Perseus Proteomics Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2018 - 2020
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	2018 - 2020
Net Income	-902	-1,102	-785	-597	-411	Upgrade
Depreciation & Amortization	2	3	5	2	-	Upgrade
Loss (Gain) From Sale of Assets	72	153	95	117	1	Upgrade
Other Operating Activities	-1	-1	-	-	-	Upgrade
Change in Accounts Receivable	-8	-3	-	-1	1	Upgrade
Change in Inventory	-	-1	-	-1	-	Upgrade
Change in Accounts Payable	8	1	22	10	-23	Upgrade
Change in Other Net Operating Assets	110	117	99	-6	10	Upgrade
Operating Cash Flow	-719	-833	-564	-476	-422	Upgrade
Capital Expenditures	-75	-143	-164	-33	-2	Upgrade
Sale (Purchase) of Intangibles	-	-15	-6	-	-	Upgrade
Other Investing Activities	-	8	-42	-	-	Upgrade
Investing Cash Flow	-75	-150	-212	-33	-2	Upgrade
Issuance of Common Stock	927	63	-	2,652	1,011	Upgrade
Other Financing Activities	-4	-	-	-5	-	Upgrade
Financing Cash Flow	923	63	-	2,647	1,011	Upgrade
Foreign Exchange Rate Adjustments	-2	16	7	8	1	Upgrade
Miscellaneous Cash Flow Adjustments	-1	1	-	-1	-2	Upgrade
Net Cash Flow	126	-903	-769	2,145	586	Upgrade
Free Cash Flow	-794	-976	-728	-509	-424	Upgrade
Free Cash Flow Margin	-661.67%	-976.00%	-774.47%	-716.90%	-632.84%	Upgrade
Free Cash Flow Per Share	-55.65	-82.80	-61.91	-46.29	-60.57	Upgrade
Cash Income Tax Paid	1	1	1	1	1	Upgrade
Levered Free Cash Flow	-592.25	-736.38	-631.63	-249.63	-269.5	Upgrade
Unlevered Free Cash Flow	-592.25	-736.38	-631.63	-249.63	-269.5	Upgrade
Change in Net Working Capital	3	22	31	-77	10	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.